title: Effect of cilostazol administration on cerebral hemodynamics and rehabilitation outcomes in poststroke patients.
abstract: OBJECTIVE
  Cilostazol is an antiplatelet agent that inhibits phosphodiesterase III in platelets and the vascular endothelium. We assessed the effects of cilostazol on human cerebral hemodynamics and rehabilitation outcomes.
  
  
  METHODS
  Prospective, consecutive, observational trial with pretreatment and posttreatment evaluations.
  
  
  METHODS
  Cilostazol (200 mg/day) administered for 8 weeks.
  
  
  METHODS
  Cerebral blood flow at rest, cerebrovascular reserve capacity, and rehabilitation outcomes (Brunnstrom stage, Barthel index score, modified Rankin Scale score, and Mini-Mental State Examination score) were measured in 104 poststroke patients with an average age ± standard deviation of 60.8 ± 9.2 years.
  
  
  RESULTS
  The cerebral blood flow increased by 23.8% on the affected side of the brain and by 16.9% on the nonaffected side. The cerebrovascular reserve capacity increased by 19.0% on the affected side of the brain and by 13.3% on the nonaffected side. Improvements were observed in the Brunnstrom stage, Barthel index score, modified Rankin Scale score, and Mini-Mental State Examination score.
  
  
  CONCLUSIONS
  Cilostazol appeared to have beneficial effects in poststroke patients with cerebral ischemia and might improve cerebral circulation and rehabilitation outcome.
authors.affiliation: Department of Rehabilitation and Physical Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kirishima City, Kagoshima, Japan. shushu@m.kufm.kagoshima-u.co.jp
authors.forename: Shuji
authors.initials: S
authors.lastname: Matsumoto
authors.forename: Megumi
authors.initials: M
authors.lastname: Shimodozono
authors.forename: Ryuji
authors.initials: R
authors.lastname: Miyata
authors.forename: Kazumi
authors.initials: K
authors.lastname: Kawahira
mesh_terms: D000328:Adult; D000368:Aged; D002545:Brain Ischemia / Q000188:drug therapy / Q000534:rehabilitation; D002536:Cerebral Arteries / Q000187:drug effects / Q000502:physiology; D002560:Cerebrovascular Circulation / Q000187:drug effects* / Q000502:physiology; D000077407:Cilostazol; D005260:Female; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care / Q000379:methods; D026741:Physical Therapy Modalities; D011446:Prospective Studies; D020521:Stroke / Q000188:drug therapy*; D000071939:Stroke Rehabilitation; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects; D055815:Young Adult
chemical_list: D013777:Tetrazoles; D014665:Vasodilator Agents; D000077407:Cilostazol